2、EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results 3、Amivantamab in EGFR Exon 20 InsertionMutated Non–Small-Cell Lung CancerProgressing on Platinum Chemotherapy: InitialResults From the CHRYSALIS Phase ...
The article discusses a study titled "Oncogenic mutations counteract intrinsic disorder in the epidermal growth factor receptor (EGFR) kinase and promote receptor dimerizationon," by Y. Shan and coworkers, published online on October 2, 2012 in the periodical "Cell." Topics include EGFR mutation,...
22. Zitvogel, L., et al.,Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance.Immunity, 2013.39(1): p. 74-88. 23. Zhang, P., et al.,Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer pa...
HLX07 has a well-validated target and its mechanism of action is relatively clear. The originator of HLX07 is cetuximab, which is a chimeric human mouse anti-EGFR mAb. Based on Henlius’ advanced antibody engineering pla...
[4]https://medicalxpress.com/news/2022-04-discovery-mcla-clinical-candidate-screened.html [5]https://www.globenewswire.com/news-release/2022/04/25/2428080/37568/en/Merus-Announces-Publication-in-Nature-Cancer-on-Petosemtamab-s-MCLA-158-Unique-Mechanism-of-Action.html...
AgentMechanism of action Afatinib Irreversible TKIb of EGFRa and HER2 Bevacizumab mAbc targeting VEGFd BMS-690514 Multitargeted TKIb of EGFR,a HER2 and VEGFRe Brivanib Multitargeted TKIb of VEGFRe and FGFRf Cabozantinib Multitargeted TKIb of MET,g VEGFR,e RET, c-KIT, FLT-3 Cixutumumab mAbc...
Epidermal growth factor receptor (EGFR) is a key regulator of cancer cell proliferation, apoptosis, invasion, and metastasis. However, the clinical benefits of EGFR targeted agents such as erlotinib and cetuximab have been modest. Using Merrimack's Network Biology platform, a computational systems ana...
aMechanism of Action: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor...
MET amplification has been identified as a primary mechanism of acquired resistance to third-generation EGFR-TKI treatment, including osimertinib [86,87,88]. Amivantamab, a bispecific monoclonal antibody targeting EGFR and MET, has unique mechanisms of action, including ligand blocking, receptor degrad...
22. Zitvogel, L., et al.,Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance.Immunity, 2013.39(1): p. 74-88. 23. Zhang, P., et al.,Upregulation of programmed cell death ligand 1 prom...